PL368636A1 - Kompozycje farmaceutyczne, postacie dawkowania i sposoby doustnego podawania epotilonów - Google Patents

Kompozycje farmaceutyczne, postacie dawkowania i sposoby doustnego podawania epotilonów

Info

Publication number: PL368636A1
Authority: PL; Poland
Prior art keywords: epothilones; dosage forms; oral administration; pharmaceutical dosage; pharmaceutical
Prior art date: 2001-01-25

Application number

PL02368636A

Other languages

English (en)

Inventor

Rebanta Bandyopadhyay

Timothy M. Malloy

Andrea Panaggio

Krishnaswamy Srinivas Raghavan

Sailesh Amilal Varia

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-25

Filing date

2002-01-25

Publication date

2005-04-04

2002-01-25 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2005-04-04 Publication of PL368636A1 publication Critical patent/PL368636A1/pl

Links

239000002552 dosage form Substances 0.000 title 1
229930013356 epothilone Natural products 0.000 title 1
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PL02368636A 2001-01-25 2002-01-25 Kompozycje farmaceutyczne, postacie dawkowania i sposoby doustnego podawania epotilonów PL368636A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US26422801P	2001-01-25	2001-01-25
US29001901P	2001-05-11	2001-05-11

Publications (1)

Publication Number	Publication Date
PL368636A1 true PL368636A1 (pl)	2005-04-04

Family

ID=26950349

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL02368636A PL368636A1 (pl)	2001-01-25	2002-01-25	Kompozycje farmaceutyczne, postacie dawkowania i sposoby doustnego podawania epotilonów

Country Status (26)

Country	Link
US (2)	US6576651B2 (pl)
EP (1)	EP1361877A1 (pl)
JP (1)	JP2004528287A (pl)
KR (1)	KR20040025888A (pl)
CN (1)	CN1268336C (pl)
AR (1)	AR035078A1 (pl)
BG (1)	BG108027A (pl)
BR (1)	BR0206695A (pl)
CA (1)	CA2434584A1 (pl)
CZ (1)	CZ20032023A3 (pl)
EE (1)	EE200300329A (pl)
HR (1)	HRP20030674A2 (pl)
HU (1)	HUP0303800A3 (pl)
IL (1)	IL156759A0 (pl)
IS (1)	IS6892A (pl)
MX (1)	MXPA03006476A (pl)
NO (1)	NO20033343L (pl)
NZ (1)	NZ526871A (pl)
PE (1)	PE20020853A1 (pl)
PL (1)	PL368636A1 (pl)
RU (1)	RU2291695C2 (pl)
SK (1)	SK9212003A3 (pl)
TW (1)	TWI250017B (pl)
UY (1)	UY27138A1 (pl)
WO (2)	WO2002058699A1 (pl)
YU (1)	YU58103A (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1386922B1 (en)	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6867305B2 (en)	1996-12-03	2005-03-15	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US20050043376A1 (en) *	1996-12-03	2005-02-24	Danishefsky Samuel J.	Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en)	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
US6780620B1 (en) *	1998-12-23	2004-08-24	Bristol-Myers Squibb Company	Microbial transformation method for the preparation of an epothilone
JP2003502449A (ja)	1999-06-10	2003-01-21	ハネウエル・インターナシヨナル・インコーポレーテツド	フォトリソグラフィ用スピンオンガラス反射防止コーティング
US6824879B2 (en)	1999-06-10	2004-11-30	Honeywell International Inc.	Spin-on-glass anti-reflective coatings for photolithography
US8618085B2 (en) *	2000-04-28	2013-12-31	Koasn Biosciences Incorporated	Therapeutic formulations of desoxyepothilones
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
SK8552003A3 (en) *	2001-01-25	2004-06-08	Bristol Myers Squibb Co	Parenteral formulation containing epothilone analogs
IL156988A0 (en)	2001-02-20	2004-02-08	Bristol Myers Squibb Co	Pharmaceutical compositions containing epothilone derivatives
ATE554756T1 (de) *	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
KR20040066124A (ko)	2001-11-15	2004-07-23	허니웰 인터내셔널 인코포레이티드	포토리소그라피용 스핀온 반사 방지 피막
US7211593B2 (en) *	2002-03-12	2007-05-01	Bristol-Myers Squibb Co.	C12-cyano epothilone derivatives
TW200403994A (en) *	2002-04-04	2004-03-16	Bristol Myers Squibb Co	Oral administration of EPOTHILONES
TW200400191A (en) *	2002-05-15	2004-01-01	Bristol Myers Squibb Co	Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
US6921769B2 (en)	2002-08-23	2005-07-26	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de)	2002-08-23	2007-01-15	Sloan Kettering Inst Cancer	Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US7649006B2 (en)	2002-08-23	2010-01-19	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
JP2006504743A (ja) *	2002-10-09	2006-02-09	コーザンバイオサイエンシスインコーポレイテッド	治療製剤
US7390503B1 (en)	2003-08-22	2008-06-24	Barr Laboratories, Inc.	Ondansetron orally disintegrating tablets
DK2792363T3 (da) *	2003-08-26	2016-09-26	Shire Biopharmaceuticals Holdings Ireland Ltd	Farmaceutisk formulering, der omfatter lanthanforbindelser
US20050171167A1 (en) *	2003-11-04	2005-08-04	Haby Thomas A.	Process and formulation containing epothilones and analogs thereof
US7883703B2 (en) *	2003-11-14	2011-02-08	The Brigham And Women's Hospital, Inc.	Methods of modulating immunity
US8053159B2 (en)	2003-11-18	2011-11-08	Honeywell International Inc.	Antireflective coatings for via fill and photolithography applications and methods of preparation thereof
US20090004277A1 (en) *	2004-05-18	2009-01-01	Franchini Miriam K	Nanoparticle dispersion containing lactam compound
US7244765B2 (en) *	2004-06-25	2007-07-17	Cytokine Pharmasciences, Inc	Guanylhydrazone salts, compositions, processes of making and methods of using
US20060069136A1 (en) *	2004-09-24	2006-03-30	Ulrich Klar	Use of Epothilones in the treatment of bone metastasis
SI1817013T1 (sl) *	2004-11-18	2008-12-31	Bristol Myers Squibb Co	Peleta z gastrorezistentno oblogo, ki vsebuje iksabepilon
WO2006055742A1 (en) *	2004-11-18	2006-05-26	Bristol-Myers Squibb Company	Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
AR057325A1 (es) *	2005-05-25	2007-11-28	Progenics Pharm Inc	Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US8158152B2 (en) *	2005-11-18	2012-04-17	Scidose Llc	Lyophilization process and products obtained thereby
US8642246B2 (en)	2007-02-26	2014-02-04	Honeywell International Inc.	Compositions, coatings and films for tri-layer patterning applications and methods of preparation thereof
CN102076339A (zh)	2008-04-24	2011-05-25	百时美施贵宝公司	埃坡霉素D在治疗包括阿尔茨海默病的τ相关疾病中的用途
US8557877B2 (en)	2009-06-10	2013-10-15	Honeywell International Inc.	Anti-reflective coatings for optically transparent substrates
DE102010021637A1 (de)	2010-05-26	2011-12-01	Bayer Schering Pharma Aktiengesellschaft	Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US8864898B2 (en)	2011-05-31	2014-10-21	Honeywell International Inc.	Coating formulations for optical elements
CN102276433B (zh) *	2011-06-30	2016-04-20	南昌大学	木豆素c及其衍生物及其在制备抗癌药物中的应用
WO2016167892A1 (en)	2015-04-13	2016-10-20	Honeywell International Inc.	Polysiloxane formulations and coatings for optoelectronic applications

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4138042C2 (de)	1991-11-19	1993-10-14	Biotechnolog Forschung Gmbh	Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE59609305D1 (de)	1995-11-17	2002-07-11	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Herstellung
DE19542986A1 (de)	1995-11-17	1997-05-22	Biotechnolog Forschung Gmbh	Epothilon-Derivate und deren Verwendung
DE19639456A1 (de)	1996-09-25	1998-03-26	Biotechnolog Forschung Gmbh	Epothilon-Derivate, Herstellung und Mittel
PL189698B1 (pl) *	1996-03-12	2005-09-30	Pg Txl Co	Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) *	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
DE19645361A1 (de)	1996-08-30	1998-04-30	Ciba Geigy Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19645362A1 (de)	1996-10-28	1998-04-30	Ciba Geigy Ag	Verfahren zur Herstellung von Epothilon A und B und Derivaten
AU716610B2 (en)	1996-08-30	2000-03-02	Novartis Ag	Method for producing epothilones, and intermediate products obtained during the production process
DE19636343C1 (de) *	1996-08-30	1997-10-23	Schering Ag	Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
ATE267197T1 (de)	1996-11-18	2004-06-15	Biotechnolog Forschung Gmbh	Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en)	1996-12-03	2001-03-20	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (en) *	1996-12-03	2012-04-11	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6441186B1 (en)	1996-12-13	2002-08-27	The Scripps Research Institute	Epothilone analogs
US6380394B1 (en)	1996-12-13	2002-04-30	The Scripps Research Institute	Epothilone analogs
DE19701758A1 (de)	1997-01-20	1998-07-23	Wessjohann Ludgar A Dr	Epothilone-Synthesebausteine
EP0975638B1 (de)	1997-02-25	2002-08-07	Gesellschaft für biotechnologische Forschung mbH (GBF)	Seitenkettenmodifizierte epothilone
DE19713970B4 (de)	1997-04-04	2006-08-31	R&D-Biopharmaceuticals Gmbh	Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja)	1997-04-18	2008-03-26	ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19720312A1 (de)	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de)	1997-05-15	1998-11-19	Biotechnolog Forschung Gmbh	Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de)	1997-06-17	1998-12-24	Schering Ag	Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) *	1997-07-08	2003-08-12	Bristol-Myers Squibb Company	Epothilone derivatives
DK1001951T3 (da)	1997-07-16	2002-12-23	Schering Ag	Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
ES2290993T3 (es)	1997-08-09	2008-02-16	Bayer Schering Pharma Aktiengesellschaft	Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
US6365749B1 (en)	1997-12-04	2002-04-02	Bristol-Myers Squibb Company	Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
KR20080016756A (ko)	1998-02-05	2008-02-21	노파르티스 아게	유기화합물 함유 조성물
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) *	1998-02-25	2003-02-21	Novartis Ag	Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2322157C (en)	1998-02-25	2012-05-29	Sloan-Kettering Institute For Cancer Research	Synthesis of epothilones, intermediates thereto and analogues thereof
US6399638B1 (en)	1998-04-21	2002-06-04	Bristol-Myers Squibb Company	12,13-modified epothilone derivatives
AU5036999A (en)	1998-06-30	2000-01-17	Schering Aktiengesellschaft	Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
CN100381566C (zh)	1998-11-20	2008-04-16	科森生物科学公司	产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt)	1998-12-22	2001-09-25	Novartis Ag	Derivados de epotilona e seu uso como agentes antitumor
EE200100431A (et)	1999-02-18	2002-12-16	Schering Aktiengesellschaft	16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
US6211412B1 (en)	1999-03-29	2001-04-03	The University Of Kansas	Synthesis of epothilones
AR023792A1 (es)	1999-04-30	2002-09-04	Bayer Schering Pharma Ag	Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
CA2434526C (en)	2001-01-25	2011-11-01	Bristol Myers Squibb Company	Methods of administering epothilone analogs for the treatment of cancer
NZ526871A (en)	2001-01-25	2006-01-27	Bristol Myers Squibb Co	Pharmaceutical dosage forms of epothilones for oral administration
ATE554756T1 (de)	2001-03-14	2012-05-15	Bristol Myers Squibb Co	Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen

2002
- 2002-01-22 NZ NZ526871A patent/NZ526871A/en unknown
- 2002-01-22 WO PCT/US2002/001693 patent/WO2002058699A1/en not_active Ceased
- 2002-01-25 PE PE2002000061A patent/PE20020853A1/es not_active Application Discontinuation
- 2002-01-25 PL PL02368636A patent/PL368636A1/pl not_active Application Discontinuation
- 2002-01-25 RU RU2003126174/15A patent/RU2291695C2/ru not_active IP Right Cessation
- 2002-01-25 EP EP02723073A patent/EP1361877A1/en not_active Withdrawn
- 2002-01-25 JP JP2002559035A patent/JP2004528287A/ja not_active Withdrawn
- 2002-01-25 CZ CZ20032023A patent/CZ20032023A3/cs unknown
- 2002-01-25 BR BR0206695-5A patent/BR0206695A/pt not_active IP Right Cessation
- 2002-01-25 EE EEP200300329A patent/EE200300329A/xx unknown
- 2002-01-25 UY UY27138A patent/UY27138A1/es not_active Application Discontinuation
- 2002-01-25 KR KR10-2003-7009781A patent/KR20040025888A/ko not_active Withdrawn
- 2002-01-25 IL IL15675902A patent/IL156759A0/xx unknown
- 2002-01-25 SK SK921-2003A patent/SK9212003A3/sk unknown
- 2002-01-25 CN CNB028069927A patent/CN1268336C/zh not_active Expired - Fee Related
- 2002-01-25 AR ARP020100288A patent/AR035078A1/es unknown
- 2002-01-25 CA CA002434584A patent/CA2434584A1/en not_active Abandoned
- 2002-01-25 YU YU58103A patent/YU58103A/sh unknown
- 2002-01-25 US US10/057,390 patent/US6576651B2/en not_active Ceased
- 2002-01-25 TW TW091101287A patent/TWI250017B/zh not_active IP Right Cessation
- 2002-01-25 HU HU0303800A patent/HUP0303800A3/hu unknown
- 2002-01-25 WO PCT/US2002/002518 patent/WO2002058701A1/en not_active Ceased
- 2002-01-25 HR HR20030674A patent/HRP20030674A2/hr not_active Application Discontinuation
- 2002-01-25 MX MXPA03006476A patent/MXPA03006476A/es unknown
2003
- 2003-07-24 NO NO20033343A patent/NO20033343L/no not_active Application Discontinuation
- 2003-07-24 BG BG108027A patent/BG108027A/bg unknown
- 2003-07-24 IS IS6892A patent/IS6892A/is unknown
2005
- 2005-06-09 US US11/149,501 patent/USRE40387E1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
RU2003126174A (ru)	2005-02-27
BR0206695A (pt)	2004-04-20
NO20033343L (no)	2003-09-24
IS6892A (is)	2003-07-24
HUP0303800A3 (en)	2005-02-28
AU2002253880B2 (en)	2006-11-09
EP1361877A1 (en)	2003-11-19
CA2434584A1 (en)	2002-08-01
WO2002058699A1 (en)	2002-08-01
NZ526871A (en)	2006-01-27
IL156759A0 (en)	2004-02-08
UY27138A1 (es)	2002-08-30
HRP20030674A2 (en)	2005-06-30
YU58103A (sh)	2006-03-03
MXPA03006476A (es)	2003-09-22
TWI250017B (en)	2006-03-01
CN1498106A (zh)	2004-05-19
AR035078A1 (es)	2004-04-14
JP2004528287A (ja)	2004-09-16
CN1268336C (zh)	2006-08-09
PE20020853A1 (es)	2002-09-27
SK9212003A3 (en)	2004-11-03
KR20040025888A (ko)	2004-03-26
US6576651B2 (en)	2003-06-10
USRE40387E1 (en)	2008-06-17
NO20033343D0 (no)	2003-07-24
WO2002058701A1 (en)	2002-08-01
US20020177615A1 (en)	2002-11-28
EE200300329A (et)	2003-10-15
BG108027A (bg)	2004-12-30
HUP0303800A2 (hu)	2004-03-29
CZ20032023A3 (cs)	2005-03-16
RU2291695C2 (ru)	2007-01-20

Legal Events

Date	Code	Title	Description
2010-05-31	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
MXPA03006476A (es)	2003-09-22	Composiciones farmaceuticas, formas de dosificacion y metodos para administracion oral de epotilonas.
PL356358A1 (en)	2003-04-07	Solid dosage form of someticone for oral administration
IL166489A (en)	2014-01-30	Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone
IL162843A0 (en)	2005-11-20	Dosage form for oral administration of a pde4 inhibitor
HUP0302319A3 (en)	2013-04-29	Pharmaceutical composition for oral administration of active ingredient
PL364621A1 (pl)	2004-12-13	Doustna postać dawkowania zawierająca nikotynę
GB0117618D0 (en)	2001-09-12	Pharmaceutical dosage form
HUP0402451A3 (en)	2008-04-28	Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
EP1624855A4 (en)	2010-05-19	PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR THE ADMINISTRATION OF HYDROPHOBIC MEDICINAL PRODUCTS
SI1390023T1 (sl)	2008-10-31	Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana
GB0117619D0 (en)	2001-09-12	Pharmaceutical dosage form
PL372773A1 (pl)	2005-08-08	Sposób podawania doustnego epotilonów
IL145559A0 (en)	2002-06-30	Tolperison-containing pharmaceutical preparation for oral administration
IL161143A0 (en)	2004-08-31	A flash-melt pharmaceutical oral dosage composition
FI20000780L (fi)	2001-10-04	Peroraalinen lääkemuoto lääkeaineen hallituksi vapauttamiseksi
IL166337A0 (en)	2006-01-16	Oral administration of calctionin
IL162510A0 (en)	2005-11-20	Pharmaceutical suspension for oral administration
AP2004003087A0 (en)	2004-09-30	Oral dosage form for controlled drug release
IL159154A0 (en)	2004-06-01	Dispenser for administration of a pharmaceutical fluid
AU2003284786A8 (en)	2004-06-23	Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
AU2003263480A8 (en)	2004-04-19	Oral pharmaceutical compositions of fenofibrate having high bioavailability
IL175556A0 (en)	2008-04-13	Pharmaceutical composition for oral administration of a pyrazol-3-carboxamide derivative
EP1361866A4 (en)	2007-10-17	EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION
HK1059035A (en)	2004-06-18	Pharmaceutical dosage forms of epothilones for oral administration
IL155855A0 (en)	2003-12-23	Pharmaceutical formulation of gepirone for oral administration